A recent trial found that rimonabant could significantly reduce alanine aminotransferase (ALT) and enhance weight loss in obese women with polycystic ovary syndrome (PCOS) who did not have non-alcoholic fatty liver disease (NAFLD) (66). The gene discussed is GPT; the disease is polycystic ovary syndrome.